Suven Life Sciences Limited share price
NSE: SUVEN · ISIN INE495B01038
Key numbers
- Market cap
- ₹ 9,466 Cr
- Current price
- ₹ 335.00
- 52-week high / low
- ₹ 403 / 124
- Stock P/E
- -
- Book value
- ₹ 22.4
- Dividend yield
- 0.00%
- ROCE
- -76.9%
- ROE
- -78.8%
- Debt to equity
- 0.03
- Sales growth (3 yrs)
- -19.3%
- Profit growth (3 yrs)
- -
- 1-year return
- 51.0%
About Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer's disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathic hypersomnia. The company also develops Ropanicant (SUVN-911), an a4ß2 nicotinic acetylcholine receptor (nAChR) antagonist for the treatment of major depressive disorder; Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for management of cognitive dysfunction; and Tenaclidine (SUVN-I6107), a muscarinic M1 positive allosteric modulator for the treatment of cognitive disorders and schizophrenia. In addition, it is involved in the development of programs, such as SUVN-M8036 Serotonin/Dopamine Modulator for psychiatric disorder indications; SUVN-D1044 5-HT4 Agonist for gastrointestinal disorders; M4 PAM for psychosis indications; P2X7…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 2 | 1 | 3 | 2 | 4 |
| Operating profit | -51 | -80 | -103 | -51 | -133 |
| Net profit | -52 | -77 | -102 | -46 | -128 |
| EPS (₹) | -2.36 | -3.48 | -4.55 | -2.02 | -4.84 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.